12:00 AM
Feb 09, 2009
 |  BC Week In Review  |  Company News  |  Other News

Enzon drug delivery, infectious, cancer news

Knott Partners, which owns about 4% of Enzon, sent a letter to CEO Jeffery Buchalter and the board suggesting immediate action, including a share buyback plan; an auction for the entire company or its specialty pharmaceutical business; and the out-licensing of one or more of Phase I programs. In December, Enzon discontinued a plan to spin off its biotechnology business, citing market conditions. The spinout was announced in May...

Read the full 323 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >